A person with haemophilia A has low or no levels of the clotting factor VIII protein. FVIII replacement therapy has long been the standard of care. FVIII replacement was first performed using donated whole blood, then plasma, and most recently, recombinant human FVIII (rFVIII) replacement therapies, which completely changed how Hemophilia A was treated.